Annotation Detail
Information
- Associated Genes
- FGFR2
- Associated Variants
-
FGFR2 FUSION
FGFR2 FUSION - Associated Disease
- cholangiocarcinoma
- Source Database
- CIViC Evidence
- Description
- This Phase II trial of BGJ398 for FGFR2 aberant cholangiocarcinoma included 48 patients with FGFR2 fusions. Among these patients with FGFR2 fusions, eight showed tumor response (18.8%) and thirty-six showed tumor shrinkage (75%).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5908
- Gene URL
- https://civic.genome.wustl.edu/links/genes/22
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2202
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cholangiocarcinoma
- Evidence Direction
- Supports
- Drug
- Infigratinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29182496
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Infigratinib | Sensitivity | true |